The other ‘C’: Hospital-acquired Clostridioides difficile infection during the coronavirus disease 2019 (COVID-19) pandemic

To the Editor — We read with interest the recent article by LeRose et al 1 on the impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infection. In contrast to their observations of increased central-line – associated infection and blood-culture contamination rates during the first wave of the COVID-19 pandemic, we observed a decrease in hospital-acquired Clostridioides difficile infection (HA-CDI) within our institution over this time, compared with the same period in previous years

COVID-19 was admitted on March 10, 2020.Daily on-site SARS-CoV-2 real-time polymerase chain reaction (PCR) testing commenced on March 16 for patients with suspected COVID-19 and for all admitted patients on April 19. 8 Daily onsite C. difficile laboratory testing continued without interruption during the first COVID-19 wave.This involves a 2-step protocol: testing for C. difficile toxin B gene tcdB by PCR and if positive, testing for C. difficile toxin.Positive results are reported by telephone daily by the clinical microbiologist, who also discusses relevance and recommended management plans.Patients are isolated with contact precautions, and on discharge, hydrogen peroxide decontamination of the area is performed prior to new patient admission.
Data on newly acquired HA-CDI from March 1 to May 31 were collected and compared to the same periods in 2018 and 2019.CDI data were extracted from the hospital CDI database.This database comprises CDI data, which are collected and validated prospectively, with assignment of CDI case type as outlined in national guidelines. 9Patient demographics and biochemical markers were collected from the patient administration systems.Hospital antimicrobial consumption and hand hygiene audit data for the same periods were also collected.One-way ANOVA using Prism software (GraphPad, San Diego, CA) was employed to determine whether there was a statistically significant difference between rates of CDI during the pandemic period versus the same periods in 2018 and 2019.
In total, 50 patients with HA-CDI were identified, and most were admitted under the care of medical specialties: 14 in 2018, 27 in 2019, and 9 in 2020 (4 of whom had COVID-19) (Table 1).Compared with the previous 2 years, hospital admissions were lower (P < .0001)and hand hygiene audit scores showed a significant improvement during the first COVID-19 wave compared with 2018 (P = .0015)and 2019 (P = .045),with no change in antimicrobial consumption.We observed a decrease in lengthof-stay in 2020, but this was not significant.Newly acquired HA-CDI decreased during the first wave of the COVID-19 pandemic period compared with the same periods in 2018 (P = .0013)and 2019 (P < .0001)(Table 1).
During the first wave of the COVID-19 pandemic in our institution, despite concerns regarding its impact on antimicrobial stewardship, antimicrobial consumption remained stable, with a reduction on HA-CDI compared to the previous 2 years.It is likely that reduced occupancy, length-of-stay, and increased emphasis on infection prevention and control, especially hand hygiene, also played a role.The interplay between the gut microbiome, COVID-19, and C. difficile has yet to be elucidated and the impact of COVID-19 on colonization resistance and risk of future CDI unknown.During additional waves of the pandemic, it is essential that CDI prevention, control and management play larger parts in the healthcare response, especially in elderly patients.Unlike the first wave, hospital activity has returned to normal levels, with full bed occupancy.Therefore, vigilance for cross infection, including HA-CDI, is of paramount importance.

Table 1 .
Details of Patients With Hospital-Acquired C. difficile Infection (HA-CDI), March 1 to May 31, 2018-2020: Hospital Activity, Antimicrobial Consumption and Hand Hygiene Compliance Note.BDU, bed days used; DDD, defined daily dose. 1 Patient an inpatient in the critical care unit at time of diagnosis of CDI.
2Antimicrobial therapy during current admission.